Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Abstract

Novel nonpeptide agents potently block the C-type inactivated conformation of Kv1.3 and suppress T cell activation.

A Nguyen, J C Kath, D C Hanson, M S Biggers, P C Canniff, C B Donovan, R J Mather, M J Bruns, H Rauer, J Aiyar, A Lepple-Wienhues, G A Gutman, S Grissmer, M D Cahalan and K G Chandy
Molecular Pharmacology December 1996, 50 (6) 1672-1679;
A Nguyen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J C Kath
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D C Hanson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M S Biggers
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P C Canniff
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C B Donovan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R J Mather
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M J Bruns
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H Rauer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J Aiyar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A Lepple-Wienhues
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G A Gutman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S Grissmer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M D Cahalan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K G Chandy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The nonpeptide agent CP-339,818 (1-benzyl-4-pentylimino-1,4-dihydroquinoline) and two analogs (CP-393,223 and CP-394,322) that differ only with respect to the type of substituent at the N1 position, potently blocked the Kv1.3 channel in T lymphocytes. A fourth compound (CP-393,224), which has a smaller and less-lipophilic group at N1, was 100-200-fold less potent, suggesting that a large lipophilic group at this position is necessary for drug activity. CP-339,818 blocked Kv1.3 from the outside with a IC50 value of approximately 200 nM and 1:1 stoichiometry and competitively inhibited 125I-charybdotoxin from binding to the external vestibule of Kv1.3. This drug inhibited Kv1.3 in a use-dependent manner by preferentially blocking the C-type inactivated state of the channel. CP-339,818 was a significantly less potent blocker of Kv1.1, Kv1.2, Kv1.5, Kv1.6, Kv3.1-4, and Kv4.2; the only exception was Kv1.4, a cardiac and neuronal A-type K+ channel. CP-339,818 had no effect on two other T cell channels (I(CRAC) and intermediate-conductance K(Ca)) implicated in T cell mitogenesis. This drug suppresses human T cell activation, suggesting that blockade of Kv1.3 alone is sufficient to inhibit this process.

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology
Vol. 50, Issue 6
1 Dec 1996
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Novel nonpeptide agents potently block the C-type inactivated conformation of Kv1.3 and suppress T cell activation.
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract

Novel nonpeptide agents potently block the C-type inactivated conformation of Kv1.3 and suppress T cell activation.

A Nguyen, J C Kath, D C Hanson, M S Biggers, P C Canniff, C B Donovan, R J Mather, M J Bruns, H Rauer, J Aiyar, A Lepple-Wienhues, G A Gutman, S Grissmer, M D Cahalan and K G Chandy
Molecular Pharmacology December 1, 1996, 50 (6) 1672-1679;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract

Novel nonpeptide agents potently block the C-type inactivated conformation of Kv1.3 and suppress T cell activation.

A Nguyen, J C Kath, D C Hanson, M S Biggers, P C Canniff, C B Donovan, R J Mather, M J Bruns, H Rauer, J Aiyar, A Lepple-Wienhues, G A Gutman, S Grissmer, M D Cahalan and K G Chandy
Molecular Pharmacology December 1, 1996, 50 (6) 1672-1679;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics